Generation of tolerogenic dendritic cells and their therapeutic applications

Seungbo Yoo, Sang Jun Ha

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that bridge innate and adaptive immune responses, thereby leading to immune activation. DCs have been known to recognize pathogen-associated molecular patterns such as lipopolysaccharides (LPS) and nucleic acids via their pattern recognition receptors, which trigger signaling of their maturation and effector functions. Furthermore, DCs take up and process antigens as a form of peptide loaded on the major histocompatibility complex (MHC) and present them to T cells, which are responsible for the adaptive immune response. Conversely, DCs can also play a role in inducing immune suppression under specific circumstances. From this perspective, the role of DCs is related to tolerance rather than immunity. Immunologists refer to these special DCs as tolerogenic DCs (tolDCs). However, the definition of tolDCs is controversial, and there is limited information on their development and characteristics. In this review, we discuss the current concept of tolDCs, cutting-edge methods for generating tolDCs in vitro, and future applications of tolDCs, including clinical use.

Original languageEnglish
Pages (from-to)52-60
Number of pages9
JournalImmune Network
Volume16
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Dendritic Cells
Adaptive Immunity
Therapeutics
Pattern Recognition Receptors
Antigen-Presenting Cells
Major Histocompatibility Complex
Innate Immunity
Nucleic Acids
Lipopolysaccharides
Immunity
T-Lymphocytes
Antigens
Peptides

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

@article{c39aa3cb4bca4c25927629d56a310242,
title = "Generation of tolerogenic dendritic cells and their therapeutic applications",
abstract = "Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that bridge innate and adaptive immune responses, thereby leading to immune activation. DCs have been known to recognize pathogen-associated molecular patterns such as lipopolysaccharides (LPS) and nucleic acids via their pattern recognition receptors, which trigger signaling of their maturation and effector functions. Furthermore, DCs take up and process antigens as a form of peptide loaded on the major histocompatibility complex (MHC) and present them to T cells, which are responsible for the adaptive immune response. Conversely, DCs can also play a role in inducing immune suppression under specific circumstances. From this perspective, the role of DCs is related to tolerance rather than immunity. Immunologists refer to these special DCs as tolerogenic DCs (tolDCs). However, the definition of tolDCs is controversial, and there is limited information on their development and characteristics. In this review, we discuss the current concept of tolDCs, cutting-edge methods for generating tolDCs in vitro, and future applications of tolDCs, including clinical use.",
author = "Seungbo Yoo and Ha, {Sang Jun}",
year = "2016",
month = "1",
day = "1",
doi = "10.4110/in.2016.16.1.52",
language = "English",
volume = "16",
pages = "52--60",
journal = "Immune Network",
issn = "1598-2629",
publisher = "Korean Association of Immunologists",
number = "1",

}

Generation of tolerogenic dendritic cells and their therapeutic applications. / Yoo, Seungbo; Ha, Sang Jun.

In: Immune Network, Vol. 16, No. 1, 01.01.2016, p. 52-60.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Generation of tolerogenic dendritic cells and their therapeutic applications

AU - Yoo, Seungbo

AU - Ha, Sang Jun

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that bridge innate and adaptive immune responses, thereby leading to immune activation. DCs have been known to recognize pathogen-associated molecular patterns such as lipopolysaccharides (LPS) and nucleic acids via their pattern recognition receptors, which trigger signaling of their maturation and effector functions. Furthermore, DCs take up and process antigens as a form of peptide loaded on the major histocompatibility complex (MHC) and present them to T cells, which are responsible for the adaptive immune response. Conversely, DCs can also play a role in inducing immune suppression under specific circumstances. From this perspective, the role of DCs is related to tolerance rather than immunity. Immunologists refer to these special DCs as tolerogenic DCs (tolDCs). However, the definition of tolDCs is controversial, and there is limited information on their development and characteristics. In this review, we discuss the current concept of tolDCs, cutting-edge methods for generating tolDCs in vitro, and future applications of tolDCs, including clinical use.

AB - Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that bridge innate and adaptive immune responses, thereby leading to immune activation. DCs have been known to recognize pathogen-associated molecular patterns such as lipopolysaccharides (LPS) and nucleic acids via their pattern recognition receptors, which trigger signaling of their maturation and effector functions. Furthermore, DCs take up and process antigens as a form of peptide loaded on the major histocompatibility complex (MHC) and present them to T cells, which are responsible for the adaptive immune response. Conversely, DCs can also play a role in inducing immune suppression under specific circumstances. From this perspective, the role of DCs is related to tolerance rather than immunity. Immunologists refer to these special DCs as tolerogenic DCs (tolDCs). However, the definition of tolDCs is controversial, and there is limited information on their development and characteristics. In this review, we discuss the current concept of tolDCs, cutting-edge methods for generating tolDCs in vitro, and future applications of tolDCs, including clinical use.

UR - http://www.scopus.com/inward/record.url?scp=85020084227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020084227&partnerID=8YFLogxK

U2 - 10.4110/in.2016.16.1.52

DO - 10.4110/in.2016.16.1.52

M3 - Review article

AN - SCOPUS:85020084227

VL - 16

SP - 52

EP - 60

JO - Immune Network

JF - Immune Network

SN - 1598-2629

IS - 1

ER -